Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC. (SGEN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/14/2017 11/15/2017 11/16/2017 11/17/2017 11/20/2017 Date
57.2(c) 57.6(c) 59.29(c) 59.79(c) 58.7 Last
696 400 1 519 492 756 325 665 770 740 333 Volume
+0.14% +0.70% +2.93% +0.84% -1.82% Change
More quotes
Financials ($)
Sales 2017 467 M
EBIT 2017 -217 M
Net income 2017 -139 M
Finance 2017 444 M
Yield 2017 -
Sales 2018 570 M
EBIT 2018 -176 M
Net income 2018 -162 M
Finance 2018 363 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 17,5x
EV / Sales2018 14,5x
Capitalization 8 605 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer.Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent,... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
11/16 SEATTLE GENETICS : Announces FDA Approval of ADCETRIS® Brentuximab Vedotin for P..
11/16 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/13 HERE’S WHAT’S MOVING SEA : SGEN) and Heron Therapeutics, Inc. (NASDA..
11/09 SEATTLE GENETICS : Submits Supplemental Biologics License Application to FDA for..
11/09 SEATTLE GENETICS : Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for..
11/09 SEATTLE GENETICS : FDA approves drug developed in Bothell to treat disfiguring b..
11/09 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/08 SEATTLE GENETICS : and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in..
11/06 SEATTLE GENETICS : WA Management's Discussion and Analysis of Financial Conditio..
11/06 TAKEDA PHARMACEUTICAL : to Showcase Data That May Reshape the Future of Blood Ca..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/14 YOUR DAILY PHARMA SCOOP : Heron Undervalued, Theravance Submits NDA, Nektar Cont..
11/12 Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
11/12 YOUR DAILY PHARMA SCOOP : Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soar..
11/11 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 11, 2017
11/10 European advisory committee selected summary of opinions/actions - November
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 64,6 $
Spread / Average Target 8,0%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Eric L. Dobmeier Chief Operating Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.13.30%8 605
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.15%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538